EUVIMEDEUVIMED entdecken
Crossref

5-O-Methylgenistein of Phaleria macrocarpa (Scheff.) Boerl. revealed as a potential therapeutic compound for endometriosis

Sutrisno Sutrisno, Maharani Maharani

Journal of Pharmacy & Pharmacognosy Research · 01.05.2026 · 14 (3) · 2658

DOI: 10.56499/jppres_14.3.2658 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy & Pharmacognosy Research, online erschienen am 01.05.2026. Verfasst von Sutrisno Sutrisno und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Endometriosis is a chronic estrogen-dependent inflammatory disorder associated with pelvic pain and infertility. Flavonoids from Phaleria macrocarpa have been reported to exhibit anti-inflammatory activity; however, their molecular mechanisms relevant to endometriosis remain insufficiently characterized.

Aims

To predict biological activities of selected P. macrocarpa flavonoids and to explore potential protein–ligand interactions with endometriosis-relevant targets using molecular docking.

Methods

Six flavonoids (eriodictyol, glycitin, 5-O-methylgenistein, catechin 7-O-β-D-xyloside, 8-prenylnaringenin, and naringenin) were assessed using the PASS web server to estimate biological activity probabilities (Pa/Pi). The compound with the highest predicted anti-inflammatory probability (Pa > 0.7) was selected for docking against cyclooxygenase-2 (COX-2), estrogen receptor (ER), AKT, aryl hydrocarbon receptor (AHR), and caspase-3 using Molegro Virtual Docker. Docking protocol validation was performed by redocking co-crystallized ligands and evaluating RMSDs.

Results

PASS prediction indicated that all compounds exhibited potential anti-inflammatory activity (Pa > Pi), with 5-O-methylgenistein showing the highest confidence prediction (Pa = 0.838). Docking analysis suggested that 5-O-methylgenistein can occupy the binding sites of COX-2, ER, AKT, and AHR, showing comparable interaction patterns and overlapping residues with those of reference ligands, as indicated by software-derived scores. Redocking validation confirmed the acceptable reproduction of the pose (RMSD ≤ 2.0 Å).

Conclusions

5-O-methylgenistein was identified as a promising candidate for further investigation. The predicted interactions support hypotheses related to inflammation- and hormone-associated pathways in endometriosis; however, these findings are based on computational models and require experimental validation to confirm biological activity and therapeutic relevance.

Zitieren

APA

Sutrisno, S., & Maharani, M. (2026). 5-O-Methylgenistein of Phaleria macrocarpa (Scheff.) Boerl. revealed as a potential therapeutic compound for endometriosis. Journal of Pharmacy & Pharmacognosy Research, 14(3), 2658. https://doi.org/10.56499/jppres_14.3.2658

Vancouver

Sutrisno S, Maharani M. 5-O-Methylgenistein of Phaleria macrocarpa (Scheff.) Boerl. revealed as a potential therapeutic compound for endometriosis. Journal of Pharmacy & Pharmacognosy Research. 2026;14(3):2658. doi:10.56499/jppres_14.3.2658

BibTeX
@article{Sutrisno2026,
  author = {Sutrisno, Sutrisno and Maharani, Maharani},
  title = {5-O-Methylgenistein of Phaleria macrocarpa (Scheff.) Boerl. revealed as a potential therapeutic compound for endometriosis},
  journal = {Journal of Pharmacy & Pharmacognosy Research},
  year = {2026},
  volume = {14},
  number = {3},
  pages = {2658},
  doi = {10.56499/jppres_14.3.2658}
}
Kostenlos starten →